Skip to main content
EuBiologics Co., Ltd. logo

EuBiologics Co., Ltd. — Investor Relations & Filings

Ticker · 206650 ISIN · KR7206650004 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country KR South Korea
Listing KO 206650

About EuBiologics Co., Ltd.

http://eubiologics.com/eng/

EuBiologics Co., Ltd. is a biopharmaceutical company focused on improving global public health through the development and supply of safe and effective vaccines. The company specializes in preventative vaccines against global pandemics and emerging infectious diseases, with a key product being its oral cholera vaccine. In addition to its vaccine pipeline, EuBiologics provides Contract Research and Manufacturing Organization (CRMO) services. These services cover the development and GMP-compliant production of mammalian cell and microbial-derived biopharmaceuticals, including protein-based therapeutics and antibodies. The company is committed to technological innovation and adhering to international standards to address global health challenges.

Recent filings

Filing Released Lang Actions
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 72% confidence The document is a voluntary disclosure (“자율공시”) by a Korean-listed company announcing the conclusion of a single sale and supply contract (단일판매ㆍ공급계약 체결) with UNICEF. It details contract amount, period, payment terms, and other non-financial-report information. It is not an annual, interim, audit, earnings, or management report, nor does it pertain to dividends, share issues, M&A, governance, or ESG. Therefore it falls into the fallback "Regulatory Filings" category (RNS).
2026-06-05 Korean
기업설명회(IR)개최
Investor Presentation Classification · 88% confidence The document is an announcement of an upcoming corporate investor relations meeting (“기업설명회(IR) 개최”) including date, time, location, target audience (analysts), agenda, and where the IR materials will be posted. It does not contain actual financial statements or slides, but it is clearly an investor presentation event notice. This corresponds to our Investor Presentation category rather than a financial report or a simple regulatory filing.
2026-05-29 Korean
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 92% confidence The document is a voluntary regulatory disclosure of a single sales and supply contract (oral cholera vaccine to UNICEF), detailing contract value, term and conditions. It does not contain financial results, management discussion, capital issuance, share transactions, legal proceedings or ESG information. It is not announcing a report or an executive certification. Therefore it falls under the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-19 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 94% confidence The document is the Korean “분기보고서” for the 17th fiscal period covering January 1 to March 31, 2026. It includes full financial statements, notes, management’s discussion and analysis, auditor opinion, and detailed corporate information, consistent with an interim/quarterly report rather than a brief earnings release or announcement. Therefore, it should be classified as an Interim / Quarterly Report. Q1 2026
2026-05-14 Korean
소속부변경
Regulatory Filings Classification · 95% confidence The document is a short announcement about a change in the company's classification or department within an exchange or regulatory framework, specifically a change from '기술성장기업부' (Technology Growth Enterprise Division) to '우량기업부' (Excellent Enterprise Division). It does not contain financial data, management changes, or detailed reports. This type of announcement fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about company classification change.
2026-04-30 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership Status of Specific Securities by Executives and Major Shareholders.' It includes detailed information about share ownership, changes in holdings, and transactions by an individual named Shin Young Hee, who is an executive (non-registered officer) of the company. The document is addressed to regulatory bodies such as the Securities and Futures Commission and the Korea Exchange, indicating it is a formal disclosure of insider holdings and transactions. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 2505 characters, which is consistent with a detailed insider transaction report rather than a full financial report or announcement. Therefore, the appropriate classification is 'DIRS' (Director's Dealing).
2026-04-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.